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INTRODUCTION
 Lipoprotein(a) [Lp(a)], is a macromolecule 
which consists of a glycoprotein apolipoprotein(a), 
which is disulfide linked to apolipoprotein B-100 
on an LDL core.1-6 Its concentrations are primarily 
genetically determined7-12, and various studies have 
shown that, high levels of Lp(a) in plasma, is an 
independent risk factor for premature atherosclerotic 
coronary artery disease.10-16 The normal metabolism 
and the role and of this lipoprotein are not fully 
elucidated.14-21 Several studies have shown, high 
concentrations of Lp(a) in diabetic patients, which 
has led to speculation that Lp(a) may contribute to 
the greatly increased incidence of vascular disease 
associated with diabetes.4,21 However, considerable 
debate still remains, regarding the precise value of 
serum Lp(a) levels in type 2 diabetes(T2D) patients. 
In non-diabetic patients, renal disease correlates 
with elevated levels of Lp(a) that are normalized by 
kidney transplantation.2,16,18,20 Kidney involvement 
is a frequent complication of diabetes that has 
prompted speculation that, kidney dysfunction is 
the principal cause of raised Lp(a) in T2D patients.2-7 
This study aimed to investigate the association 
of serum Lp(a) level with various indexes of 
demographic and biochemical of T2D patients.
METHODOLOGY
Patients: This cross-sectional study was conducted 
on a group of T2D patients who were  admitted 
in the hospital for controlling the diabetes with 
either insulin injection or oral hypoglycemic 
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ABSTRACT
To examine the association of serum serum lipoprotein(a)[Lp(a)] concentration with various demographic 
and biochemical indexes of diabetic patients , we conducted a study on type 2 diabetes mellitus(T2D) 
patients. Patients were under treatment with insulin injection or oral hypoglycemic agents with various 
creatinine clearances not yet on dialysis. We studied 122 patients, with a mean age of 63 ± 10 years .The 
duration	of	diabetes	was	7.4	±	5.8	years.	In	this	cross-sectional	study,	serum	Lp(a),	HbA1c , body mass index 
(BMI)	and	creatinine	clearance	were	assessed.	The	mean	serum	Lp(a)	was	22.2	±	24.7	mg/dL	(median:	
18.3	mg/dL),	and	serum	Lp(a)	levels	more	than	30	mg/dL	was	found	in	29	(23.8%)	patients.	A	significant	
inverse correlation of serum Lp(a) with clearance of creatinine was observed. This study suggests that 
renal function is an independent determinant of serum Lp(a) in diabetic patients.
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Lipoprotein (a) in diabetic patients
agents. Exclusion criteria included presence of any 
infections and use of lipid-lowering medications. 
All patients signed consent forms for participation 
in this study.
Laboratory tests: After admission to hospital, 
detailed medical history was obtained, and careful 
physical exam was performed. Serum Lp(a) were 
measured by enzyme-linked immunosorbent 
assay kit (Macra® Lp(a) manufactured by Strategic 
Diagnostics Inc. for Trinity Biotech USA, Jamestown, 
NY, USA). Results were expressed in mg/dL; the 
intra- and inter assay coefficients of variation for 
this method were < 5% and < 10%, respectively. 
Serum Lp(a) levels of 30 mg/dL was considered 
as the threshold value of risk for its pathological 
effect. Serum glycosilated hemoglobine (HbA1c) 
was measured by chromatography method using 
Hb-Gold of UK; normal level in our laboratory is 
up to 6.1%. Levels of serum albumin (Alb), serum 
creatinine (Cr), blood urea nitrogen (BUN) total 
protein, triglyceride (TG), cholestrol (chol), and 
high density lipoprotein (HDL-C) were measured 
using standard methods. Body mass index (BMI) 
was assessed using the standard formula.22 Serum 
LDL-C was calculated by friedewald’s formula.23 
Creatinine clearance was evaluated from serum 
creatinine, age and body weight.24
Statistical analysis: Data are expressed as the 
mean ± SD and median values. For correlations we 
used the partial correlation test. For comparison 
between females and males student’s t test was 
used. To normalize of the serum Lp(a) data, the 
cube root of Lp(a) was assessed and used. All 
analyses were performed with the SPSS statistical 
package (version 11.0 for Windows; SPSS, Chicago). 
Statistical significance was determined at value of 
p <0.05.
RESULTS
 In Table-I the baseline characteristics of the 
study patients are shown. One hundred twenty 
two patients (40 males, 82 females) with a mean 
age of 63 ± 10 years, was enrolled to this study. 
The mean duration of diabetes were 7.4 ± 5.8 years 
(median: 6 years). The mean serum Lp(a) was 22.2 
± 24.7 mg/dl (median: 18.3 mg/dl). Serum Lp(a) 
levels > 30 mg/dl was found in 29 patients (23.8%). 
The mean of creatinine clearance was 64± 24. We 
found a significant inverse correlation of duration 
of diabetes mellitus (DM) with creatinine clearance 
(r= - 0.51, p < 0.001).A significant inverse correlation 
of serum Lp(a) with creatinine clearance (r= - 0.19, 
p= 0.03) was seen. We did not find a significant 
correlation of serum Lp(a) with age, or DM, BMI, 
serum Alb, total protein, lipids or serum HgA1C.
DISCUSSION
 Our results demonstrated a significant inverse 
correlation of duration of DM and serum Lp(a) 
with creatinine clearance. There was no significant 
correlation of serum Lp(a) with age, BMI, serum 
Alb, total proteins, lipids and serum HgA1c. Serum 
Lp(a) levels > 30 mg/dl was found in 23.8% of 
patients. Recent studies suggest that Lp(a) can act as 
a marker for determining vascular or tissue injury.25 
Table-I: Patients’ data and laboratory tests of the 122 study patients.
Parameters Minimum Maximum Mean±SD Median
Age (years) 25 84 63±11 64
Duration of DM (years) 0.1 25 7.4±6.8 6
BMI (kg/m2) 30 53 25.5±4.5 25.3
Systolic blood pressure (mmHg) 100 180 138±23 80
Diastolic blood pressure (mmHg) 50 130 83±12 140
Creatinine clearance (ml/min) 10 110 64±24 64
Lipoprotein(a) (mg/dl) 0.10 134 22.2±24.8 18.3
Albumin (g/dl) 2.5 7.5 4.9±1 4.9
Total protein (g/dl) 5 12.5 7.2±0.9 7
HgbA1C % 3.9 13.5 7.6±1.9 7.6
Cholestrol (mg/dl) 90 38.8 198±52 192
Triglyceride (mg/dl) 37 580 183±102 155
LDL-C (mg/dl) 44 210 112±37 112
HDL-C (mg/dl) 19 128 47±18 44
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Recent findings have also demonstrated that Lp(a) 
is an independent risk factor for the progression 
of diabetic nephropathy in T2D patients.26,27 
Indeed macroalbuminuria was associated with 
raised plasma Lp(a) regardless of the marker 
used to identify kidney failure.28-42 Moreover, 
altered kidney function, is a major determinant 
of raised Lp(a) levels in microalbuminuric and 
normoalbuminuric diabetics patients.34,35 Increase 
in plasma Lp(a) levels was seen in various studies 
in nondiabetics.34-42 Increased levels of Lp(a) is an 
independent risk factor for vascular disease in the 
general population and in diabetic patients.43-54 In 
view of these findings, defining the relationship 
between renal complications and levels of serum 
Lp(a) in diabetic patients is mandatory.
CONCLUSION
 Our results suggest that serum Lp(a) concentration 
was associated with clearance of creatinine as a 
primary determinant of raised serum Lp(a) in 
diabetic patients. This has important implications 
for the increased susceptibility to vascular disease 
associated with Lp(a) in diabetic patients.
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